Haverford Financial Services Inc. Sells 456 Shares of Johnson & Johnson (NYSE:JNJ)

Haverford Financial Services Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 59,978 shares of the company’s stock after selling 456 shares during the period. Johnson & Johnson makes up 2.6% of Haverford Financial Services Inc.’s holdings, making the stock its 18th largest position. Haverford Financial Services Inc.’s holdings in Johnson & Johnson were worth $8,766,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Richardson Financial Services Inc. grew its holdings in shares of Johnson & Johnson by 21.5% in the 2nd quarter. Richardson Financial Services Inc. now owns 497 shares of the company’s stock valued at $73,000 after buying an additional 88 shares during the period. WCG Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson by 13.0% in the 2nd quarter. WCG Wealth Advisors LLC now owns 12,124 shares of the company’s stock valued at $1,772,000 after buying an additional 1,395 shares during the period. AllGen Financial Advisors Inc. grew its holdings in shares of Johnson & Johnson by 14.0% in the 2nd quarter. AllGen Financial Advisors Inc. now owns 36,088 shares of the company’s stock valued at $5,275,000 after buying an additional 4,443 shares during the period. Kendall Capital Management grew its holdings in shares of Johnson & Johnson by 5.1% in the 2nd quarter. Kendall Capital Management now owns 7,543 shares of the company’s stock valued at $1,102,000 after buying an additional 365 shares during the period. Finally, Miramar Capital LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $258,000. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on JNJ shares. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. The Goldman Sachs Group reduced their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 30th. TD Cowen reduced their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Finally, Morgan Stanley upped their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Trading Down 0.5 %

Johnson & Johnson stock opened at $166.17 on Thursday. The firm has a 50-day moving average of $160.71 and a 200-day moving average of $154.09. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The company has a market cap of $399.92 billion, a price-to-earnings ratio of 10.36, a P/E/G ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.80 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.98%. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.